A Phase I, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Inhaled APN01
Latest Information Update: 08 Nov 2022
At a glance
- Drugs Alunacedase alfa (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Proof of concept
- Sponsors Apeiron Biologics
- 03 Nov 2022 According to an invIOs media release, the study met all primary and secondary endpoints.
- 03 Nov 2022 Results presented in an invIOs media release.
- 22 Sep 2022 Status changed from recruiting to completed.